Hyderabad, May 19, 2015
Shares of Dr Reddy’s Labs jumped nearly 3 per cent to hit intraday high of Rs 3,591.80 after the company on Friday said that it has launched a drug for treatment of post-stroke patients.
Dr Reddy’s Labs has launched Somazina in the Indian markets. the drug’s is innovator brand is Citicoline. Dr. Reddy’s has partnered with the global innovator of Citicoline, Ferrer Internacional S.A., Spain, to make Somazina available in India.
Somazina is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries.
Citicoline is a widely used neuro-protectant to help accelerate the recovery of these patients. It is used in both ischemic and haemorrhagic strokes, and provides a compelling option to physicians treating stroke patients.
The stock reacted positively to this news. The stock closed 3.6 per cent at Rs 3,622. Business Line
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…